Agilent Technologies Delivers Strong Q4 Results with Double-Digit Earnings Surge, Projects Mid-Single-Digit Q1 Growth

Agilent Technologies, Inc. (A), a leading provider of laboratory instruments, software, services, and consumables, posted robust fourth quarter performance ending October 31, 2025, with net income catapulting 25 percent year-over-year to $434 million, or $1.53 per share, compared to $351 million and $1.22 per share in the prior-year quarter. Adjusting for non-GAAP metrics, earnings climbed 9 percent to $452 million or $1.59 per share from $418 million or $1.46 per share.

The company’s Q4 revenue expanded to $1.861 billion from $1.701 billion last year, reflecting accelerating demand across its core business lines. The three operational divisions—Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets—each contributed meaningfully to this performance.

Segment-by-Segment Performance Breakdown

Both Life Sciences and Diagnostics Markets and Agilent CrossLab segments emerged as primary growth engines, with each generating $755 million in Q4 2025 revenue against $657 million and $706 million, respectively, in the year-ago quarter. This represents notable sequential improvements in the Life Sciences division while maintaining Agilent CrossLab’s competitive position. The Applied Markets segment, though smaller, still demonstrated positive momentum, rising to $351 million from $338 million annually.

Forward Guidance and Market Outlook

For the upcoming first quarter ending January 31, 2026, Agilent projects revenue between $1.79 billion and $1.82 billion—implying a 6 percent to 8 percent increase year-over-year from the prior $1.68 billion. Non-GAAP earnings per share guidance sits at $1.35 to $1.38, up from $1.31 in Q1 2025.

Longer-term, the company anticipates full fiscal year 2026 revenues in the $7.3 billion to $7.4 billion range and non-GAAP EPS between $5.86 and $6.00. This contrasts with fiscal 2025’s $6.95 billion in revenue and $5.59 in non-GAAP EPS, signaling sustained growth trajectory.

Investor Context

Over the trailing twelve months, Agilent’s stock has traded between $96.43 and $153.84, reflecting the volatility common in the analytical and diagnostic technology sector.